share_log

SVB Leerink Downgrades Design Therapeutics to Market Perform, Announces $6 Price Target

Benzinga ·  Aug 15, 2023 05:18

SVB Leerink analyst Joseph Schwartz downgrades Design Therapeutics (NASDAQ:DSGN) from Outperform to Market Perform and announces $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment